Stock Ratings / Health Care / EMBC / earnings

MOBI (50) CLPT (19) OFIX (42) SI (44) ⌘ Pro Terminal →

Embecta Corp. (EMBC) Next Earnings Date & Expected ±9.6% Move

$6.25 -4.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.18

Embecta Corp. (EMBC) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $354.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EMBC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EMBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Embecta Corp. (NASDAQ: EMBC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $6.25 (-4.73% 1D, market cap $354.1M). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, EMBC ranks #96 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EMBC compare to MOBI and CLPT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), EMBC carries a Roarable C+ (68/100 RQD), trailing P/E of 3.9x, gross margin of 62.6%, and ROIC of 35.5%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and CLPT (ClearPoint Neuro Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $342.0M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EMBC?

▼

Per EMBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001872789), Embecta Corp. generated $1.08B in revenue (-3.8% YoY), $95.4M in net income, and $182.4M in free cash flow against $1.06B in total assets and $1.35B in total debt. Key quantitative strengths: Strong cash generator (63% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.19 (-1.04%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 16.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EMBC)Realized 20D OHLCV Swing Band: ±9.6%

Deterministic 5-Pillar Attribution (68/100 Composite)

🔍 WHY EMBC SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 16.9% FCF Margin ($182.4M FCF) & 62.6% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$6.20+3.5% Next Q

Q2 (-2Q)

Grade C+$6.42+2% Next Q

Q3 (-1Q)

Grade C+$6.55-4.6% Next Q

Current

Grade C+$6.25+1.8% Hist 90D α

Trajectory: C (60) → C+ (68)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the EMBC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, EMBC faces multiple-compression risk if 3.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 60.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.79) or 200D SMA ($6.38) invalidates the momentum regime and cuts Target Base ($6.53) toward Bear Floor ($5.09).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EMBC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EMBC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 68%NO 32%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 29, 2026 (~56 DAYS)

Historical OHLCV Volatility ±9.6% Swing Band

±$0.60 Expected Swing

MODEL EARNINGS SETUP GAUGE

EMBC Quantitative Pre-Earnings Setup: 68/100

Trailing EPS: $1.68 • YoY Revenue Growth: -3.8%

Model Bullish Setup (68/100)Model Risk Weight (32/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-09-30	$1.08B	$95.4M	$182.4M	62.6%
FY 2024	2024-09-30	$1.12B	$78.3M	$19.9M	65.5%
FY 2023	2023-09-30	$1.12B	$70.4M	$67.7M	62.6%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating EMBC & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on EMBC
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EMBC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.43%▲ ASCENDING CHANNEL

2026-11-03O $6.56H $6.56L $6.25C $6.25VOL 831.1K

RES: $7.14SUP: $3.73SMA50: $5.79SMA200: $6.38

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EMBC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EMBC Butterfly Map → + Track EMBC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-15.0%/yr Implied 5Y Growth

vs. -3.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EMBC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EMBC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EMBC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EMBC)

Health Care Rank #96 of 1016 ⚔️ MOBI vs EMBC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EMBC vs. MOBI, CLPT, OFIX, SI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Embecta Corp. (EMBC) ranks #96 by composite RQD confidence (68/100, grade C+) and #494 by equity capitalization ($354.1M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EMBC ACTIVE Embecta Corp.	C+	68/100	3.9x	62.6%	35.5%	-4.73%	$354.1M	Benchmark Subject
MOBI Mobia Medical Inc.	D	50/100	—	—	—	-6.12%	$352.2M	/mobi-vs-embc →
CLPT ClearPoint Neuro Inc.	E	19/100	—	61.4%	-35.0%	-0.19%	$342.0M	/clpt-vs-embc →
OFIX Orthofix Medical Inc.	D-	42/100	—	68.8%	-12.2%	-11.43%	$369.4M	/ofix-vs-embc →
SI Shoulder Innovations Inc.	D	44/100	—	76.5%	-16.1%	-6.41%	$398.3M	/si-vs-embc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001872789

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Embecta Corp. (EMBC) reported GAAP revenue of $1.08B (-3.8% vs. FY2024 revenue of $1.12B , and -3.6% cumulative change since FY2023) , GAAP net income of $95.4M, operating cash flow of $191.7M, and free cash flow of $182.4M (+816.6% YoY). On the balance sheet, EMBC closed FY2025 with $1.06B in total assets against $1.35B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$1.08B	$95.4M	$191.7M	$182.4M	$1.06B	$1.35B
FY2024 (FY)	2024-09-30	$1.12B	$78.3M	$35.7M	$19.9M	$1.15B	$1.53B
FY2023 (FY)	2023-09-30	$1.12B	$70.4M	$67.7M	$67.7M	—	—

3. EMBC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EMBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EMBC compare to MOBI and CLPT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EMBC?

Where is EMBC trading relative to its 50-day, 200-day, and 52-week technical levels?

EMBC last traded at $6.25 (-4.73% on volume of 831,126 shares), positioning the stock +7.94% above its 50-day simple moving average ($5.79) and -2.04% below its 200-day simple moving average ($6.38). Across its 52-week range of $2.77 to $14.91, EMBC sits at the 28.7% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($5.65 to $6.85).

EMBC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is EMBC's next earnings date?

Based on SEC filing cadence, Embecta Corp. (EMBC)'s next quarterly reporting window is estimated around Dec 29, 2026.

How much is EMBC stock expected to move on earnings?

Volatility modeling currently projects a ±9.6% event move for EMBC, spanning a range between $5.65 and $6.85.

Direct Sub-Reports: EMBC RQD Cockpit EMBC 12M Forecast EMBC Earnings & Move EMBC Dividends & DRIP EMBC Insiders & 13F EMBC Whale Options EMBC Profit Sankey EMBC News & Why

ROARABLE RATING BRIEF • RQD 68/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EMBC — Embecta Corp.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:37:32Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EMBC scores 74 out of 100, a letter grade of B, with the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are:

Fundamental Cash Engine: 19 / 20. Per the RQD rating, this pillar reflects an ROIC of 35.5% alongside an FCF yield of 0%. The strong return on invested capital is the primary upside driver in this pillar, while the zero FCF yield is a valuation tradeoff: the reported free cash flow is not being returned to shareholders at the current market price.
Whale 13F Flow: 11 / 20. Per the RQD rating, this pillar measures institutional accumulation and options positioning. The modest score suggests institutional flow is a weaker supporting factor than the fundamentals. Holder data in the source is not available, so the underlying positioning cannot be examined further here.
Insider Conviction: 17 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. This is a relatively strong score, though the underlying trade detail is not available in the source data.
Macro Regime Fit: 12 / 20. Per the RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity to broad moves; the score indicates moderate rather than favorable macro alignment.
Forensic Balance Sheet: 15 / 20. Per the RQD rating, this pillar reflects an Altman Z of 2.5, a Piotroski F of 7/9, and a Debt/Equity of 0.5. These support solvency and fundamental quality, but the reported debt level is a key consideration for a prospective investor.

Taken together, the rating points to strong cash-generation economics and reasonable forensic health, offset by weaker institutional flow and macro fit. For a prospective investor evaluating the stock today, the central question is whether the high ROIC and low trailing valuation outweigh the leverage and the absence of free-cash-flow yield.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
$6.56	$371.7M	3.9	3.6	6.1	1.68	9.42%	1.0	$2.77 - $14.91	35.5%

Business

Embecta Corp. (EMBC) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the company profile, its market capitalization is $0.4B. Per the market data, its gross margin is 62.6%, operating margin 22.4%, and net margin 8.8%. Product, customer, and revenue-model detail is not available in source data.

Recent Catalysts & News Wire Analysis

The news wire contains six items dated within roughly the prior 15 hours of the data timestamp. Per the news feed, the items are labeled as follows:

Risk Watch (RED): "What Embecta Bears Saw Before A 55% Drop" (Yahoo Finance) and "Did Embecta's 52% Fall Catch You Out? What Investors Missed" (Simply Wall St). Both reference large declines in the stock, but the underlying causes are not available in source data.
Market Wire (YELLOW): A Stocktwits general overview; an analyst-insights piece from The Globe and Mail naming EMBC alongside AIRS; a law-firm notice from The National Law Review stating that Bronstein, Gewirtz & Grossman, LLC is investigating Embecta Corp. (EMBC) and encouraging stockholders to connect; and a kalkine.ca item noting a 6.86% move on light volume with no catalyst found.

Per the news feed, the investigation notice is the most specific item; its substance and any allegations are not available in source data. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Open Questions

What drove the reported 52–55% declines referenced in the news wire, and are they tied to the investigation notice?
What is the nature of the investigation referenced by the law-firm notice, and what allegations, if any, are involved?
Why is the FCF yield 0% when reported FY 2025 free cash flow is $182.4M, and how does that reconcile with the market capitalization?
What is the composition of the $1352.9M debt, including maturities and refinancing exposure?
What EPS values were reported for the financial periods, given that the source lists them as N/A?

EMBC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Embecta Corp. (EMBC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EMBC Debate Forum (3) ↓

🟡 MARKET WIRE Stocktwits • 19h ago

EMBC: Embecta Corp Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 22h ago

What Embecta Bears Saw Before A 55% Drop

Yahoo Finance report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Analysts Offer Insights on Healthcare Companies: Embecta Corporation (EMBC) and Airsculpt Technologies (AIRS)

The Globe and Mail report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The National Law Review • 1d ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Embecta Corp. (EMBC) And Encourages Stockholders to Connect

The National Law Review report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

Why Is Embecta (NASDAQ:EMBC) Up 6.86% on Light Volume With No Catalyst Found?

kalkine.ca report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

Did Embecta's 52% Fall Catch You Out? What Investors Missed

Simply Wall St report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Embecta Q3 Earnings Call Highlights

TradingView report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

How Embecta Corp. (EMBC) Affects Rotational Strategy Timing

Stock Traders Daily report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EMBC Bull vs. Bear Conversation Board — What's Your Call at $6.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EMBC 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $7.74 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EMBC (B • RQD 74/100) a Buy at $6.56?

Welcome to the EMBC (Embecta Corp.) Roar Pit. Current RQD Composite is 74/100 (Roarable Buy — Good Risk/Reward) in Medical/Dental Instruments. Bulls point to capital efficiency (35.5% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.51 (-16.0%)

Spot @ $6.56

Pump the brakes on EMBC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EMBC, but look at what you are paying: 3.9x trailing P/E with 62.6% gross margins. Unless Embecta Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.81 (+19.1%)

Spot @ $6.56

EMBC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EMBC, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $6.56 (52-wk range $2.77 - $14.91), any beat on forward guidance forces shorts and underweight funds to chase.